Zika DNA vaccine shows promise in early trial

News Hour:

An investigational synthetic DNA vaccine (GLS-5700) seems to prompt an immune response against the Zika virus, but researchers caution that more data are needed on the vaccine’s long-term safety and efficacy, according to a phase 1, industry-supported trial in the New England Journal of Medicine.

Forty healthy adults received 1 or 2 mg of the vaccine at baseline, 4 weeks, and 12 weeks. Injections were followed by electroporation (use of a pulsed electric field to introduce the DNA into cells).

At 14 weeks, all patients had Zika-specific binding antibodies. Roughly 70% of the serum samples had 90% inhibition of Zika infection.

Next, mice were injected with the post-vaccination serum and then given a lethal dose of Zika; 92% survived. The authors write: “This finding suggests that the antibody response generated by the vaccine was protective in this infection model.”

Avatar

This article has been posted by a News Hour Correspondent. For queries, please contact through [email protected]
No Comments

Translate this News

Join the Facebook Group

Click here to join the Facebook group of News Hour

Popular Posts

Sacred Games exposes Rajshri Deshpande nude [video]
Yageo Corp to acquire Kemet Corp in a $1.8 billion deal
Anurag Kashyap shoots Kubra Saith 7 times nude and made her cry for frontal nudity scene [Video]
A ransomware attack hit computer servers and halted administrative work at Pemex
Paperfly launches delivery services covering 64 districts in Bangladesh
Grameenphone brings in the iPhone 11 series in Bangladesh

Advertisement

News of the Month

October 2017
S M T W T F S
« Sep   Nov »
1234567
891011121314
15161718192021
22232425262728
293031  
Scroll Up
%d bloggers like this: